HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Taurine enhances the antitumor efficacy of PD-1 antibody by boosting CD8+ T cell function.

Abstract
The functional state of CD8+ T cells determines the therapeutic efficacy of PD-1 blockade antibodies in tumors. Amino acids are key nutrients for maintaining T cell antitumor immunity. In this study, we used samples from lung cancer patients treated with PD-1 blockade antibodies to assay the amino acids in their serum by mass spectrometry. We found that lung cancer patients with high serum taurine levels generally responded to PD-1 blockade antibody therapy, in parallel with the secretion of high levels of cytotoxic cytokines (IFN-γ and TNF-α). CD8+ T cells cultured with exogenous taurine exhibited decreased apoptosis, enhanced proliferation, and increased secretion of cytotoxic cytokines. High SLC6A6 expression in CD8+ T cells was positively associated with an effector T cell signature. SLC6A6 knockdown limited the function and proliferation of CD8+ T cells. RNA sequencing revealed that SLC6A6 knockdown altered the calcium signaling pathway, oxidative phosphorylation, and T cell receptor signaling in CD8+ T cells. Furthermore, taurine enhanced T cell proliferation and function in vitro by stimulation of PLCγ1-mediated calcium and MAPK signaling. Taurine plus immune checkpoint blockade antibody significantly attenuated tumor growth and markedly improved the function and proliferation of CD8+ T cells in a mouse tumor model. Thus, our findings indicate that taurine is an important driver for improving CD8+ T cell immune responses and could serve as a potential therapeutic agent for cancer patients.
AuthorsYu Ping, Jiqi Shan, Yaqing Liu, Fengsen Liu, Liuya Wang, Zhangnan Liu, Jieyao Li, Dongli Yue, Liping Wang, Xinfeng Chen, Yi Zhang
JournalCancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 72 Issue 4 Pg. 1015-1027 (Apr 2023) ISSN: 1432-0851 [Electronic] Germany
PMID36261540 (Publication Type: Journal Article)
Copyright© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Chemical References
  • Programmed Cell Death 1 Receptor
  • Taurine
  • Antineoplastic Agents
  • Cytokines
  • Antibodies, Monoclonal
  • Amino Acids
Topics
  • Animals
  • Mice
  • CD8-Positive T-Lymphocytes
  • Programmed Cell Death 1 Receptor
  • Taurine (pharmacology, metabolism)
  • Antineoplastic Agents (pharmacology)
  • Cytokines (metabolism)
  • Antibodies, Monoclonal (pharmacology)
  • Disease Models, Animal
  • Lung Neoplasms (drug therapy, metabolism)
  • Amino Acids (metabolism, pharmacology)
  • Tumor Microenvironment

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: